| Daniel Hyunjae Lee, MD | |
|
5777 E Mayo Blvd, Phoenix, AZ 85054-4502 | |
| (480) 342-2347 | |
| Not Available |
| Full Name | Daniel Hyunjae Lee |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 5 Years |
| Location | 5777 E Mayo Blvd, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659833176 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 61627 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic - Arizona | 7012829930 | 1395 |
News Archive
Researchers from the Washington University School of Medicine, United States of America, recently demonstrated that the SARS-CoV-2 surface proteins alone triggered innate cell activity and the interferon signaling pathway.
KYTHERA Biopharmaceuticals, Inc. today announced four abstracts will be presented at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla.
Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.
Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.
Clinicians are being urged to ask about a patient's history of falls as new research shows that the information is valuable in determining their future risk of fracture.
› Verified 5 days ago
| Entity Name | Mayo Clinic Arizona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558332494 PECOS PAC ID: 7012829930 Enrollment ID: O20031105000782 |
News Archive
Researchers from the Washington University School of Medicine, United States of America, recently demonstrated that the SARS-CoV-2 surface proteins alone triggered innate cell activity and the interferon signaling pathway.
KYTHERA Biopharmaceuticals, Inc. today announced four abstracts will be presented at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla.
Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.
Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.
Clinicians are being urged to ask about a patient's history of falls as new research shows that the information is valuable in determining their future risk of fracture.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Hyunjae Lee, MD 5777 E Mayo Blvd, Phoenix, AZ 85054-4502 Ph: (480) 342-2347 | Daniel Hyunjae Lee, MD 5777 E Mayo Blvd, Phoenix, AZ 85054-4502 Ph: (480) 342-2347 |
News Archive
Researchers from the Washington University School of Medicine, United States of America, recently demonstrated that the SARS-CoV-2 surface proteins alone triggered innate cell activity and the interferon signaling pathway.
KYTHERA Biopharmaceuticals, Inc. today announced four abstracts will be presented at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla.
Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.
Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.
Clinicians are being urged to ask about a patient's history of falls as new research shows that the information is valuable in determining their future risk of fracture.
› Verified 5 days ago
Dr. Timur Raghib, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 1919 E Thomas Rd, Phoenix, AZ 85016 Phone: 602-933-0777 | |
Dr. Kenneth Veiga, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1930 E Thomas Rd, Phoenix, AZ 85016 Phone: 602-532-1000 | |
Patrick S Sciara, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 19829 N 27th Ave, Phoenix, AZ 85027 Phone: 623-879-1866 Fax: 623-879-1876 | |
Lindley T Bliss, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 350 W Thomas Rd, Phoenix, AZ 85013 Phone: 602-615-5672 Fax: 902-978-0158 | |
Dr. Nina Souders, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1919 E Thomas Rd, Phoenix, AZ 85016 Phone: 602-933-0777 | |
Reina Manilal Patel, D.O. Hospitalist Medicare: Medicare Enrolled Practice Location: 1919 E Thomas Rd, Phoenix, AZ 85016 Phone: 602-933-0777 Fax: 602-933-0755 | |
Homan Salehi, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9201 W Thomas Rd, Phoenix, AZ 85037 Phone: 623-327-7313 Fax: 623-327-5437 |